ARTICLE
26 December 2022

Health Canada's New Amendments On Cannabis Research, Testing And Cannabis Beverages

GW
Gowling WLG

Contributor

Gowling WLG is an international law firm built on the belief that the best way to serve clients is to be in tune with their world, aligned with their opportunity and ambitious for their success. Our 1,400+ legal professionals and support teams apply in-depth sector expertise to understand and support our clients’ businesses.
On Dec. 9, 2022, Health Canada announced the approval of the proposed amendments introduced by the Regulations Amending Certain Regulations Concerning Cannabis Research...
Canada Cannabis & Hemp
To print this article, all you need is to be registered or login on Mondaq.com.

On Dec. 9, 2022, Health Canada announced the approval of the proposed amendments introduced by the Regulations Amending Certain Regulations Concerning Cannabis Research as well as the Order Amending Schedule 3 to the Cannabis Act.

These amendments increase the public possession limit for cannabis beverages, and facilitate non-therapeutic cannabis research and testing. Health Canada anticipates publishing the amendments in Canada Gazette Part II on Dec. 22, 2022.

The amendments are intended to provide increased consistency across cannabis product possession limits, and improve the regulation of research, testing, and analysis. Among other things, the amendments:

  • Introduce a definition for "cannabis beverage" to the Cannabis Regulations;
  • Add a distinct dry cannabis equivalency amount for cannabis beverages in Schedule 3 of the Cannabis Act;
  • Increase public possession limits for cannabis beverages to 17.1 litres of cannabis beverages for non-medicinal purposes;
    • The limit translates to roughly up to 48 cans of cannabis beverage of 355ml compared to the previous limit only allowing for up to five;
    • Strict controls to address risks of accidental or overconsumption, such as limits on THC amounts per container and child-resistant packaging, remain in place;
  • Introduce a definition for "non-therapeutic research on cannabis";
  • Simplify the regulation of non-therapeutic cannabis research with human participants to provide for a more easy-to-navigate research process;
    • The requirements for clinical trials under the Food and Drug Regulations (FDR) will no longer need to be met;
    • Research can now be conducted solely under the Cannabis Regulations;
    • Researchers will be allowed to investigate cannabis and its effects from a non-therapeutic perspective.

The amended regulations will include transition periods for existing licensed researchers and cannabis beverage producers.

Read the original article on GowlingWLG.com

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

ARTICLE
26 December 2022

Health Canada's New Amendments On Cannabis Research, Testing And Cannabis Beverages

Canada Cannabis & Hemp

Contributor

Gowling WLG is an international law firm built on the belief that the best way to serve clients is to be in tune with their world, aligned with their opportunity and ambitious for their success. Our 1,400+ legal professionals and support teams apply in-depth sector expertise to understand and support our clients’ businesses.
See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More